SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

Enzo Biochem, Inc. ENZ NYSE

NYSE • Healthcare • Medical - Diagnostics & Research • US • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

Enzo Biochem, Inc. (ENZ) is a Medical - Diagnostics & Research company in the Healthcare sector, currently trading at $0.31. It has a SharesGrow Score of 36/100, indicating a weak investment profile with 0 out of 7 criteria passed.

Financials: revenue is $32M, -25.8%/yr average growth. Net income is $26M (loss), growing at -266%/yr. Net profit margin is -81.7% (negative). Gross margin is 45.9% (+0.4 pp trend).

Balance sheet: total debt is $4M against $56M equity (Debt-to-Equity (D/E) ratio 0.06, conservative). Current ratio is 2.82 (strong liquidity). Debt-to-assets is 4.1%. Total assets: $86M.

Analyst outlook: 1 / 2 analysts rate ENZ as buy (50%) — moderate consensus.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 15/100 (Fail), Past 50/100 (Partial), Health 67/100 (Partial), Moat 39/100 (Fail), Future 40/100 (Partial), Income 10/100 (Fail).

ENZ SharesGrow Score Overview

37/100

SharesGrow Score

Below average — proceed with caution

View full scorecard →

VALUE 0/100

Valuation — P/E, PEG, Forward PEG

GROWTH 15/100

Financials — average growth

PAST 50/100

strong — trend

HEALTH 67/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 39/100

Gross margin is + market cap

FUTURE 40/100

Analyst outlook — as buy

INCOME 10/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — ENZ

No analyst coverage available for this stock.

ENZ: -25.8%/yr revenue is, -266%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

ENZ: 2 / 4 years profitable. weak. Score = 2 / 4 × 100. ≥ 80 = Pass.

View details →

Balance sheet ENZ: Debt-to-Equity (D/E) ratio 0.06 (conservative), Current ratio is 2.82 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

ENZ: Gross margin is 45.9% (+0.4 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 39/100. ≥ 70 = Pass.

View details →

Analyst outlook: 1 / 2 analysts rate ENZ as buy (50%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.

View details →

ENZ: Net profit margin is -81.7%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.

View details →

Stock Chart & Stats

Market Data

52-Week Range0.252-1.275

Volume4.12M

Avg Volume (30D)348.83K

Market Cap$16.44M

Beta (1Y)1.16

Dividend Yield$0.4000

Share Statistics

EPS (TTM)-0.51

Shares Outstanding$50.9M

IPO Date1980-06-12

Employees125

CEOKara Cannon

Financial Highlights & Ratios

Revenue (TTM)$31.91M

Gross Profit$14.63M

EBITDA$-8.35M

Net Income$-26.08M

Operating Income$-9.82M

Total Cash$52.37M

Total Debt$3.51M

Net Debt$-48.86M

Total Assets$85.76M

Price / Earnings (P/E)-0.6

Price / Sales (P/S)0.52

Analyst Forecast

Rating ConsensusBuy

Analysts Covering2

Buy 50% Hold 50% Sell 0%

Company Info

CountryUS

ExchangeNYSE

CurrencyUSD

ISINUS2941001024

Price Chart

ENZ

Enzo Biochem, Inc. ↗ · NYSE

Healthcare • Medical - Diagnostics & Research

0.25 52WK RANGE 1.28

People Also View

Sotera Health Company

Olink Holding AB (publ)

Castle Biosciences, Inc.

Genetron Holdings Limited

FONAR Corporation

Neuronetics, Inc.

Sera Prognostics, Inc.

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message